Herpes Vaccine (BNT163-01)
Brief description of study
Dr. Tebas in the Division of Infectious Disease at the University of Pennsylvania is looking for volunteers ages 18-55 with a history of recurrent HSV-2 genital herpes to participate in a study evaluating an investigational mRNA-based vaccine for the prevention of genital lesions.
The study consists of 9 study visits to the Perelman Center for Advanced Medicine, during which time the study staff will collect vitals, blood samples, swabs, and provide 3 doses of the investigational mRNA vaccine. Volunteers will be paid each visit for their time and travel.
Detailed description of study
If you agree to join the study, you will be asked to complete the following research procedures:
- Receive 3 doses of a study vaccine (BNT163) and complete an injection diary
- Have your medical information reviewed
- Undergo examinations including, but not limited to, an electrocardiogram (ECG), physical exam, urine test, genital swabs
- Blood tests to determine if you are healthy
- Undergo genetic testing
- Have blood collected for the duration of the study
The study consists of 9 visits over approximately a year and a half, but additional visits may be needed for safety.
Please note that this study requires in-person clinical visits at the University of Pennsylvania Perelman Center for Advanced Medicine, located in Philadelphia.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: HSV-2 Genital Herpes
-
Age: 18 years - 55 years
-
Gender: All
To participate in this trial, you must meet the following criteria:
- Have a body mass index (BMI) over 18.5 kg/m2 and under 35 kg/m2 and weigh at least 50 kg at initial visit.
- Be willing and able to comply with scheduled visits, treatment schedule and laboratory tests
- Be overall healthy in the investigator's clinical judgment based on medical history, physical examination, 12-lead ECG, vital signs, and screening laboratory tests (blood clinical laboratory) at initial visit.
- Have had a diagnosis of recurrent genital lesions caused by herpes confirmed in medical records in the past.
- Be willing to refrain from ongoing daily use of antiviral therapy throughout study. Please note that limited use (3 days) for individual episodes is allowed throughout most of the study.
- Cannot be pregnant or infant feeding.
Please choose between Voice or SMS based delivery of verification code
or